Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Halabi, 2008, Pain predicts overall survival in men with metastatic castration-refractory prostate cancer, J Clin Oncol, 26, 2544, 10.1200/JCO.2007.15.0367 Autio, 2013, Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure, J Oncol Pract, 9, 223, 10.1200/JOP.2013.000876 Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, 1756, 10.1200/JCO.1996.14.6.1756 Kantoff, 1999, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study, J Clin Oncol, 17, 2506, 10.1200/JCO.1999.17.8.2506 Serafini, 1998, Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial, J Clin Oncol, 16, 1574, 10.1200/JCO.1998.16.4.1574 Sartor, 2004, Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer, Urology, 63, 940, 10.1016/j.urology.2004.01.034 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Basch, 2013, Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial, Lancet Oncol, 14, 1193, 10.1016/S1470-2045(13)70424-8 Fizazi, 2014, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, Lancet Oncol, 15, 1147, 10.1016/S1470-2045(14)70303-1 Loriot, 2015, Lancet Oncol, 16, 509, 10.1016/S1470-2045(15)70113-0 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Basch, 2014, Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective, Cancer, 120, 761, 10.1002/cncr.28470 Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol Cancer Ther, 10, 2298, 10.1158/1535-7163.MCT-11-0264 Stern, 2014, Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption, J Cell Biochem, 115, 2033 Nguyen, 2013, Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling, PLoS One, 8, e78881, 10.1371/journal.pone.0078881 Dai, 2014, Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions, Clin Cancer Res, 20, 617, 10.1158/1078-0432.CCR-13-0839 Haider, 2015, Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo, Bone, 81, 581, 10.1016/j.bone.2015.08.003 Basch, 2015, Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort, Eur Urol, 67, 310, 10.1016/j.eururo.2014.02.013 Smith, 2013, Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J Clin Oncol, 31, 412, 10.1200/JCO.2012.45.0494 Smith, 2014, Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study, J Clin Oncol, 32, 3391, 10.1200/JCO.2013.54.5954 Smith, 2016, Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1, J Clin Oncol, 34, 3005, 10.1200/JCO.2015.65.5597 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Atkinson, 2010, The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: clinical trial endpoint considerations, Pain Med, 11, 337, 10.1111/j.1526-4637.2009.00774.x National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, v. 1.2016. Prostate cancer. 2015. National Comprehensive Cancer Network Web site. https://www.nccn.org/professionals/physician_gls/default.aspx. Brown, 2012, Computer-aided quantitative bone scan assessment of prostate cancer treatment response, Nucl Med Commun, 33, 384, 10.1097/MNM.0b013e3283503ebf Basch, 2014, Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE), J Natl Cancer Inst, 106 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Scher, 2017, Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer, Cancer Res, 77, 5687, 10.1158/0008-5472.CAN-17-1353